摘要
目前全球大约有3亿人患哮喘,其中多数患者通过吸入免疫抑制剂(如糖皮质激素)和β-肾上腺素受体激动剂治疗哮喘,获得良好的效果。然而大约5%~10%的哮喘患者却对这种治疗反应效果较差。以信号通路中关键性激酶和核转录因子作为靶点治疗过敏性哮喘,多年来一直受到国内外学者的关注。本文就近年来激酶和核转录因子抑制剂治疗哮喘的进展进行综述。
Currently,about 300 million people worldwide are affected by asthma.Most of these sufferers inhale immunosuppressants(ie corticosteroids) and β-adrenergic receptor agonists for their asthma treatment.However,about 5%-10% of patients of asthma have poor response to such treatment.Investigation of kinase signaling pathway and nuclear transcription factor as a target molecule in the treatment of allergic asthma has been the concern of scholars home and abroad.This paper reviewed inhibitors of kinase signaling pathway and nuclear transcription factors for the treatment of asthma.
出处
《药学学报》
CAS
CSCD
北大核心
2012年第6期689-695,共7页
Acta Pharmaceutica Sinica
基金
国家自然科学基金资助项目(81001442)
中央级公益性科研院所基本科研业务费资助项目(2011CHX04)
关键词
哮喘
酪氨酸激酶
丝/苏氨酸激酶
核转录因子
气道高反应性
asthma
tyrosine kinase
serine/threonine kinase
nuclear transcription factor
airway hyper-responsiveness